English | Español
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
Patient Daily | May 7, 2023

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Patient Daily Report | May 5, 2023

Eli Lilly on new Alzheimer's drug: 'We are extremely pleased that donanemab yielded positive clinical results'
Patient Daily | May 4, 2023

Device Talks Boston 2023
Patient Daily | May 4, 2023

RELIAS ANNOUNCES UPDATES TO LEARNER MOBILE APP
Patient Daily | May 4, 2023

Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients
Mifeed | May 4, 2023

LeanTaaS Earns Highest Ratings in Inaugural KLAS Capacity Optimization Management Report

Trending
+ Pharmaceuticals
Patient Daily | Oct 23, 2025

Empower seeks dismissal of Eli Lilly suit in Texas federal court
Patient Daily | Oct 23, 2025

Dallas Breathe Free ENT Specialist: Humidity 'tends to help' with sinus issues
+ Pharmaceuticals
Patient Daily | Oct 29, 2025

Paragon Health Institute senior fellow: 340B program 'needs real reform'
Patient Daily | Oct 23, 2025

Capitol Breathe Free Otolaryngologist: ‘Allergy exacerbations are a common trigger for sinus infections'